This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Shire Pharmaceuticals Group PLC
Drug Names(s): full-length parathyroid hormone, PTH 1-84
Description: BioMedTracker has separate drug profiles for PTH-184. Please also see Natpara, as it is known in the U.S.
A recombinant human parathyroid hormone, which differs from currently available antiresorptive treatments because it is anabolic. That means it has the potential to reverse bone loss rather than just reduce bone resorption.
Deal Structure: Revenue splits for this drug are BioMedTracker estimates.
NPS and Nycomed
In April 2004, NPS Pharmaceuticals and Nycomed Group announced that they have signed a distribution and license agreement granting Nycomed rights to develop and market PREOS in Europe, including the Commonwealth of Independent States (CIS) and Turkey.
Nycomed will be responsible for European clinical development, registration and marketing of PREOS. Nycomed has agreed to make an equity investment in NPS of $40 million by purchasing common shares subject to customary closing conditions, pay NPS up to $25 million in milestones upon regulatory approvals and achievement of certain sales targets, and pay NPS royalties on sales in Europe. Nycomed will also be responsible for conducting Phase IIIb and IV clinical trials in Europe, representing a minimum additional investment of $25 million.
NPS announced in July 2007 that the company and its partner Nycomed have entered an agreement...See full deal structure in Biomedtracker
Partners: DRI Capital Inc.
Additional information available to subscribers only: